Rafael Holdings RFL
NYSE RFL
$1.53 +0.03 (+2.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Rafael Holdings (RFL) Gains from Sales and Divestitures (2023 - 2025)

Updated

Rafael Holdings (RFL) reported Gains from Sales and Divestitures of $54,000 for fiscal Q1 2026 (quarter ended Oct 31, 2025).

Analysis

Rafael Holdings (RFL) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

For FY2025 (ended Jul 31, 2025), Rafael Holdings posted Gains from Sales and Divestitures of -$81,000.

  • By fiscal year, Gains from Sales and Divestitures came in at $27,000 in FY2024.
  • The fiscal Q1 2026 figure ranks as the lowest quarterly Gains from Sales and Divestitures since fiscal Q1 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Rafael Holdings 78.35 Mn 83.76 Mn 163,000.00
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2025 54,000.00
Oct 31, 2023 27,000.00
API Access

Rafael Holdings Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=RFL&period=max&api_key=YOUR_API_KEY